Skip to main content

Table 2 Clinical, serological, and immunological features of relapsing and nonrelapsing patients at baseline and after treatment with glucocorticoids

From: Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse

  Relapsers (n = 10) Nonrelapsers (n = 5) p Value
Definite IgG4-RD (%) 9 (90%) 5 (100%)  
Probable IgG4-RD (%) 1 (10%) 0 (0%)  
Possible IgG4-RD (%) 0 (0%) 0 (0%)  
Age, yr, median 69 (60–71) 73 (64–80) 0.13
Male, n (%) 9 (90%) 3 (60%)  
Multiorgan involvement (> 1 organ) 7 (70%) 4 (80%)  
Baseline
 ESR (0–20 mm/h) 10 (9–23) 15 (8–20) 0.59
 CRP (< 6 mg/L) 5 (4–6.5) 10 (5–46) 0.06
 IgG4-RD RI (0–3) 9 (6–9) 12 (9–12) 0.22
 Eosinophils (< 300 cell/μl) 300 (300–500) 200 (150–300) 0.034
 Serum IgG4 (< 135 mg/dl) 364 (232–1090) 498 (328–947) 0.5
 IgE (mU/ml) 308 (2–1488) 733 (271–1554) 0.11
 Prednisone dose (mg/d) 5 (0–5.5) 5 (2.5–5) 0.99
 CD19+ B cells (cells/ml) 138,500 (97,500–172,500) 144,000 (103,000–162,000) 0.66
 CD20+ B cells (cells/ml) 114,000 (86,250–150,000) 128,000 (82,000–140,500) 0.57
 Naive B cells (cells/ml) 14,170 (9518–24,198) 11,170 (2915–38,650) 0.35
  Percentage of CD19+ B cells 11.4 (9.5–13.7) 11.52 (2.33–24.37) 0.09
 Memory B cells (cells/ml) 20,450 (10,790–36,070) 48,590 (11,305–62,095) 0.44
  Percentage of CD19+ B cells 15.79 (10.25–23.9) 26.48 (6.9–47.88) 0.67
 Plasmablasts (cells/ml) 3280 (985–9868) 5400 (3825–8000) 0.39
  Percentage of CD19+ B cells 3.26 (0.84–7.8) 3.38 (2.06–4.82) 0.76
 Plasma cells (cells/ml)a 420 (0–1332) 489 (146–1300) 0.86
  Percentage of CD19+ B cellsa 0.37 (0–1.27) 0.27 (0.1–0.49) 0.95
After 6 mo of treatment
 ESR (0–20 mm/h) 5 (3–21) 9 (8–20) 0.29
 CRP (< 6 mg/L) 2 (1–2.25) 2 (1.5–4) 0.47
 IgG4-RD RI (0–3) 2.5 (1.75–3.25) 2 (2–2.5) 0.62
 Eosinophils (< 300 cell/μl) 200 (100–325) 100 (100–200) 0.37
 Serum IgG4 (< 135 mg/dl) 182.5 (107–729) 257 (211–406) 0.42
 IgE (mU/ml) 107 (2–299) 425 (384–466) 0.13
 Prednisone dose (mg/d) 5 (0–5.62) 5 (2.5–5) 0.99
 CD19+ B cells (cells/ml) 174,500 (93,750–222,250) 128,000 (64,500–157,500) 0.2
 CD20+ B cells (cells/ml) 165,000 (84,750–208,500) 128,000 (52,500–154,000) 0.24
 Naive B cells (cells/ml) 7860 (3988–13,585) 7380 (2950–15,460) 0.8
 Percentage of CD19+ B cells 3.51 (2.57–4.13) 9.27 (4.16–15.73) 0.1
 Memory B cells (cells/ml) 60,540 (21,148–75,428) 18,360 (9045–34,650) 0.05
  Percentage of CD19+ B cells 27.46 (19.06–34.9) 24.19 (6.43–37.65) 0.89
 Plasmablasts (cells/ml) 355 (138–1263) 1310 (565–3350) 0.07
  Percentage of CD19+ B cells 0.27 (0.07–0.53) 0.88 (0.36–5.3) 0.03
 Plasma cells (cells/ml)a 56 (0–333) 143 (0–423) 0.22
  Percentage of CD19+ B cellsa 0.05 (0–0.32) 0.19 (0–0.53) 0.16
  1. Abbreviations: CRP C-reactive protein; ESR erythrocyte sedimentation rate; IgG4-RD RI IgG4-Related Disease Responder Index
  2. Results are expressed as median (IQR), except where indicated otherwise
  3. a Results expressed as mean (range)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us

\